|Bid||990.40 x 0|
|Ask||991.00 x 0|
|Day's Range||980.80 - 998.60|
|52 Week Range||936.20 - 1,486.00|
|PE Ratio (TTM)||48.06|
|Earnings Date||Aug 8, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1,355.59|
Genmab A/S (Nasdaq Copenhagen: GEN) announced today that at a board meeting the board decided to grant 5,305 restricted stock units and 14,714 warrants to employees of the company and two of the company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 962.
In this article I am going to calculate the intrinsic value of Genmab A/S (CPSE:GEN) using the discounted cash flows (DCF) model. Anyone interested in learning a bit more aboutRead More...
Media Release Copenhagen, Denmark; May 29, 2018– Genmab A/S announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the Goldman Sachs 39 th Annual Global Healthcare Conference ...
By Danilo Masoni and Helen Reid MILAN (Reuters) - Italian stocks slumped on Monday at the end of a roller-coaster session as investors fretted that new elections could see anti-establishment parties win ...
Italy's FTSE MIB benchmark index fell 2.1 percent to its lowest level since early March, while the pan-European STOXX 600 index shed 0.3 percent on a day when activity was limited by market holidays in Britain and the United States. The Italian index had risen as much as 2 percent in early trade after Italy's president vetoed the Five-Star and League parties' choice of a eurosceptic economy minister.
European stocks fell Monday, as investors monitored signs of thawing tensions between the U.S. and North Korea and reacted to renewed political turmoil in Italy.
Based on a recent planned review, the Data Monitoring Committee (DMC) recommends Phase Ib/II study of daratumumab plus atezolizumab (anti PD-L1 antibody) in patients with previously treated non-small cell lung cancer to be terminated.
Genmab A/S (Nasdaq Copenhagen: GEN) announced today that topline results from the Phase III study of Arzerra® (ofatumumab) plus bendamustine did not meet the primary endpoint of improved progression-free survival (PFS) in patients with indolent B-cell non-Hodgkin's lymphoma (iNHL) who were unresponsive to rituximab or a rituximab-containing regimen, compared to those given bendamustine alone. The safety profile observed in this study was consistent with that observed in other trials of ofatumumab and no new safety signals were observed.
Seven industry sponsored abstracts regarding Genmab programs scheduled for presentation at EHA Annual Congress Two oral presentations, five poster presentations. Copenhagen, Denmark; May 17, 2018– Genmab ...
Copenhagen, Denmark; May 15, 2018– Genmab A/S will increase its share capital by 155,576 shares as a consequence of the exercise of employee warrants.. The increase is effected without any preemption rights ...
Genmab A/S (Nasdaq Copenhagen: GEN) announced today that the U.S. Food and Drug Administration (U.S. FDA) has approved the use of DARZALEX® (daratumumab) in combination with bortezomib, melphalan and prednisone (VMP) for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). The supplemental Biologics License Application (sBLA) for this indication was submitted by Genmab’s licensing partner, Janssen Biotech, Inc., in November 2017.
11 industry sponsored abstracts regarding Genmab programs scheduled for presentation at ASCO Annual Meeting One oral presentation, three poster discussion sessions and seven poster presentations. Copenhagen, ...
Net sales of DARZALEX in the first quarter of 2018 totaled USD 432 million Genmab will receive royalties on worldwide sales from Janssen Biotech, Inc.. Copenhagen, Denmark; April 17, 2018– Genmab A/S announced ...
Genmab plans to own a bigger share of drugs in its early-stage pipeline as Europe's biggest biotechnology company prepares to reduce its reliance on a blockbuster cancer drug, marketed by partner Johnson & Johnson. Genmab has morphed from a cash-burning operation into a profitable business especially due to the success of blood cancer drug Darzalex, on which it is paid a royalty of 12 to 20 percent on sales of the drug. "We have the ambition to keep at least 50 percent of the ownership of all the coming drugs on our own hands and maybe we can take it to the finish line," said chief executive officer Jan van de Winkel, speaking to reporters before the group's annual shareholder meeting on Tuesday.
Genmab A/S webcast presentation now available for on-demand viewing: dbVIC - Deutsche Bank ADR Virtual Investor Conference
Company invites individual and institutional investors, as well as advisors, to log-on to view the presentation COPENHAGEN, Denmark , March 26, 2018 /PRNewswire/ -- Genmab A/S (CPH: GEN, OTC:GMXAY), focused ...
NEW YORK , March 21, 2018 /PRNewswire/ -- Deutsche Bank today announced the addition of presenters for its Depositary Receipts Virtual Investor Conference ("dbVIC") on March 22 nd , featuring ...
International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on March 22, 2018
Genmab A/S to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on March 22, 2018
COPENHAGEN, Denmark, March 21, 2018 /PRNewswire/ -- Genmab A/S (CPH: GEN.CO, OTC Pink: GMXAY), focused on the creation and development of differentiated antibody therapeutics for the treatment of cancer, today announced that Genmab's Senior Vice President, IR & Communications, Rachel Curtis Gravesen, will present at the dbVIC - Deutsche Bank American Depositary Receipt (ADR) Virtual Investor Conference on March 22, 2018. This virtual investor conference is aimed exclusively at introducing global companies with ADR programs to investors.
LONDON/MILAN (Reuters) - Mergers and acquisitions dominated European share trading on Tuesday, while strength in oil stocks after a pipeline shutdown helped lift a key regional benchmark index to five-week highs. The pan-European STOXX 600 index climbed 0.7 percent to its highest level since Nov. 9, while euro zone blue chip stocks rose 0.4 percent, helped by a late drop in the euro. Gemalto surged 34.6 percent after French tech consultancy Atos tabled an all-cash bid valuing the Dutch cybersecurity company at 4.3 billion euros.
Genmab was Europe's second biggest biotech company, until its partner Johnson & Johnson bought Switzerland's Actelion for $30 billion (£22.30 billion) this year and propelled the Danish antibody specialist to the top spot. Now some investors wonder if the same fate might await Genmab, worth $12 billion, given the soaraway success of its blood cancer drug Darzalex. J&J sells the drug and pays Genmab a royalty of 12 to 20 percent.